COMMUNIQUÉS West-GlobeNewswire

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
20/11/2024
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced [...]
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
20/11/2024
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the [...]
Lexicon Appoints Ivan H. Cheung to Board of Directors
20/11/2024
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical [...]
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
20/11/2024
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Verrica Announces Proposed Public Offering
20/11/2024
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
20/11/2024
Nyxoah to Participate in the Piper Sandler 36 th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Nyxoah Participera à la Piper Sandler 36th Annual Healthcare Conference
20/11/2024
Nyxoah Participera à la Piper Sandler 36 th Annual Healthcare Conference Mont-Saint-Guibert, Belgique – 20 Novembre 2024, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société [...]
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
20/11/2024
FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36 th [...]
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
20/11/2024
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy [...]
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/11/2024
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum’s Board of Directors granted an [...]
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
20/11/2024
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires
20/11/2024
Daix (France), Long Island City (New York, Etats-Unis), le 20 novembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules [...]
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
20/11/2024
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024
20/11/2024
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www.inventivapharma.com Date Nombre de titres composant le capital en circulation Nombre total [...]
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
20/11/2024
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. [...]
LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases
20/11/2024
LPX- TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic [...]
Court Filing against the Biden Administration’s Censorship Activities by the Association of American Physicians and Surgeons Educational Foundation Supports Its Expanded Allegations of Wrongdoing by the Federal Government
20/11/2024
TUCSON, Ariz., Nov. 20, 2024 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons Educational Foundation (“AAPS”) filed its reply in support of adding allegations against the censorship activities of [...]
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
20/11/2024
After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms among ~320 Veterans [...]
Guerbet annonce le lancement commercial en France d’Elucirem® (Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM).
20/11/2024
Guerbet annonce le lancement commercial en France d’Elucirem ® (Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM). Villepinte, le 20 novembre 2024 : Guerbet ( [...]

Pages